Ribometrix
Raquel C. Martínez Chacín, Ph.D. has over 10 years of experience in scientific research. Since 2020, they have worked as a Scientist II and Scientist I at Ribometrix Inc. From 2015 to 2020, they were a Postdoctoral Researcher and PhD Candidate in Pharmacology at the University of North Carolina at Chapel Hill. During their time there, they discovered a novel mechanism of activation of the Anaphase Promoting Complex / Cyclosome (APC/C), identified a druggable surface for modulating APC/C activity, characterized a cell penetrating peptide, and identified peptide inhibitors of the interaction between the cancer testis antigen MAGE-A4 and the E3 ligase RAD18. From 2010 to 2015, they were an HHMI Undergraduate Research Fellow and Research Assistant, Student Laboratory Assistant, and Welch Undergraduate Research Scholar at The University of Texas Rio Grande Valley. During this time, they helped determine the role of environmental factors in precocious puberty and the risk for breast cancer, determined the effects of dietary metals on the reproductive system, guided students on how to approach case studies and journal articles related to human physiology, and assessed the environmental health of the Upper Laguna Madre.
Raquel C. Martínez Chacín, Ph.D. obtained their Bachelor of Science (B.S.) from The University of Texas Rio Grande Valley in 2013, majoring in Chemistry and minoring in Biochemistry & Biology. Raquel C. then went on to pursue a Doctor of Philosophy (PhD) in Pharmacology at the University of North Carolina at Chapel Hill, which they completed in 2020.
Ribometrix
Ribometrix, headquartered in Durham, North Carolina, is a biotechnology company leveraging world-leading expertise in three-dimensional structural analysis of RNA as the foundation of its proprietary drug discovery platform. This platform enables the identification of novel small molecules that modulate the function of RNA and proteins associated with human disease. Ribometrix’ value creation strategy is built around developing an internal pipeline of drug candidates and partnerships with the leading biopharmaceutical companies. Ribometrix is backed by a syndicate of blue-chip venture investors.